Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies

By Bornstein Gadi   Quéva Christophe   Tabrizi Mohammad   Abbema Anne   Chavez Carlos   Wang Ping   Foord Orit   Ahluwalia Kiran   Laing Naomi   Raja Sandhya   Wen Shenghua   Green Larry   Yang Xiaodong   Webster Carl   Stewart Ross   Blakey David  

Investigational New Drugs, Vol. 28, Iss. 5, 2010-10 ,pp. : 561-574

Springer Publishing Company

Access to resources Recommend Favorite

Anti-CD20 Antibody in Primary Sjogren’s Syndrome Management

By  

Current Pharmaceutical Biotechnology, Vol. 15, Iss. 6, 2014-06 ,pp. : 535-541

Bentham Science Publishers

Access to resources Recommend Favorite

Development of Anti-CD20 Antigen-Targeting Therapies for B-cell Lymphoproliferative Malignancies - The State of the Art

By  

Current Drug Targets, Vol. 17, Iss. 9, 2016-07 ,pp. : 1072-1082

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting B Cells in SLE: The Experience with Rituximab Treatment (Anti-CD20)

By  

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 6, Iss. 4, 2006-12 ,pp. : 345-350

Bentham Science Publishers

Access to resources Recommend Favorite

A review of the second-generation antihistamine ebastine for the treatment of allergic disorders

By Van Cauwenberge Paul   De Belder Tine   Sys Lien  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 8, 2004-08 ,pp. : 1807-1813

Informa Healthcare

Access to resources Recommend Favorite